Filing Flows › Atrium Therapeutics (RNA) › Q2 2026 › vs Q1 2026
Atrium Therapeutics (RNA) Q2 2026 vs Q1 2026 (quarter over quarter)
Atrium Therapeutics's revenue fell $16.6M (-85%) from $19.6M in Q1 2026 to $3.0M in Q2 2026.
Atrium Therapeutics, Q2 2026: revenue $3.0M (-22% year over year), operating margin -752.9%, net loss $20.2M, operating cash flow −$3.9M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $3.0M | $19.6M | −$16.6M | -85% |
| Other income, net | $2.4M | $647K | $1.8M | +276% |
| Net loss | $20.2M | $16.6M | $3.6M | +21% |
| Costs & expenses | $25.6M | $36.9M | −$11.3M | -31% |
| Operating costs | $25.6M | $36.9M | −$11.3M | -31% |
| Research & development | $15.3M | $16.7M | −$1.3M | -8% |
| General & admin | $10.3M | $20.3M | −$10.0M | -49% |
| Operating cash sources | $20.2M | $16.6M | $3.6M | +21% |
| Depreciation | $343K | $151K | $192K | +127% |
| Share-based compensation | $893K | $12.2M | −$11.3M | -93% |
| Working capital & other | $15.0M | −$26.9M | $41.9M | — |
| Cash used in operations | $3.9M | $31.1M | −$27.2M | -87% |
| Net loss absorbed | $20.2M | $16.6M | $3.6M | +21% |
Questions
How much did Atrium Therapeutics's revenue grow quarter over quarter in Q2 2026?
Atrium Therapeutics's revenue fell $16.6M (-85%) from $19.6M in Q1 2026 to $3.0M in Q2 2026.